Brinker Capital Investments’s ADMA Biologics ADMA Stock Holding History

Brinker Capital Investments’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$187K	Sell	20,786 -9,429	-31%	-$149K	﹤0.01%	1880
2025 Q4	$551K	Buy	30,215 +7,891	+35%	+$133K	﹤0.01%	1556
2025 Q3	$327K	Sell	22,324 -42,263	-65%	-$724K	﹤0.01%	1725
2025 Q2	$1.18M	Buy	64,587 +26,759	+71%	+$546K	0.01%	1096
2025 Q1	$751K	Buy	+37,828	New	+$654K	0.01%	1218
2023 Q4	–	Sell	-11,152	Closed	-$39.9K	–	1650
2023 Q3	$39.9K	Sell	11,152 -2,118	-16%	-$8.15K	﹤0.01%	1599
2023 Q2	$49K	Hold	13,270	–	–	﹤0.01%	1614
2023 Q1	$43.9K	Sell	13,270 -869	-6%	-$3K	﹤0.01%	1546
2022 Q4	$54.9K	Buy	+14,139	New	+$43.6K	﹤0.01%	1330

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Brinker Capital Investments's ADMA Position: Q1 2026 in Review

Brinker Capital Investments reduced its ADMA Biologics (ADMA) stake by 31% in Q1 2026, selling an estimated $149K and leaving 20,786 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

Brinker Capital Investments first reported a position in ADMA in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.18M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Brinker Capital Investments held 20,786 shares of ADMA Biologics worth $187K as of Q1 2026.
Brinker Capital Investments sold 9,429 ADMA Biologics shares in Q1 2026, an estimated $149K.
ADMA Biologics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q1 2026, its #1880 holding.
Brinker Capital Investments first reported a position in ADMA Biologics in Q4 2022 and has held it in 9 quarters since.
Brinker Capital Investments's ADMA Biologics position peaked at $1.18M in Q2 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.